E2F4 regulatory program predicts patient survival prognosis in breast cancer

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Khaleel, Sari S ^a   Andrews, Erik H ^a   Ung, Matthew ^a   DiRenzo, James ^a   Cheng, Chao ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TRANSCRIPTION FACTOR E2F4; E2F4 PROTEIN, HUMAN; TRANSCRIPTOME;

AGE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NOTTINGHAM PROGNOSTIC INDICATOR; SURVIVAL TIME; BREAST TUMOR; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA; CHROMATIN IMMUNOPRECIPITATION; E2F4 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TRANSCRIPTOME;

EID: 84924276447     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0486-7     Document Type: Article

References (59)

1. Liotta L, Petricoin E: Molecular profiling of human cancer. Nat Rev Genet 2000, 1:48-56.
2. Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl Res 2009, 154:277-287.
3. Veer LJ V 't, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
4. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
5. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
6. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
7. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005, 102:13550-13555.
8. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953-R964.
9. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ: Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012, 104:1068-1079.
10. Eckhoff K, Flurschutz R, Trillsch F, Mahner S, Janicke F, Milde-Langosch K: The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol 2013, 139:1673-1680.
11. Haq R, Fisher DE: Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011, 29:3474-3482.
12. Mitchell PJ, Tjian R: Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989, 245:371-378.
13. Helin K: Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998, 8:28-35.
14. Barkett M, Gilmore TD: Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924.
15. Ogino H, Ochi H, Reza HM, Yasuda K: Transcription factors involved in lens development from the preplacodal ectoderm. Dev Biol 2012, 363:333-347.
16. Kako K, Ishida N: The role of transcription factors in circadian gene expression. Neurosci Res 1998, 31:257-264.
17. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A, Postigo A: EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012, 69:3429-3456.
18. Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002, 2:740-749.
19. Suva ML, Riggi N, Bernstein BE: Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
20. Nebert DW: Transcription factors and cancer: an overview. Toxicology 2002, 181-182:131-141.
21. Cheng C, Yan X, Sun F, Li LM: Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinformatics 2007, 8:452.
22. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM: Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005, 37:579-583.
23. Cheng C, Li LM: Systematic identification of cell cycle regulated transcription factors from microarray time series data. BMC Genomics 2008, 9:116.
24. Zhu M, Liu CC, Cheng C: REACTIN: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 2013, 14:504.
25. Cheng C, Ung M, Grant GD, Whitfield ML: Transcription factor binding profiles reveal cyclic expression of human protein-coding genes and non-coding RNAs. PLoS Comput Biol 2013, 9:e1003132.
26. Schwemmle S, Pfeifer GP: Genomic structure and mutation screening of the E2F4 gene in human tumors. Int J Cancer 2000, 86:672-677.
27. Lee BK, Bhinge AA, Iyer VR: Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysis. Nucleic Acids Res 2011, 39:3558-3573.
28. Souza RF, Yin J, Smolinski KN, Zou TT, Wang S, Shi YQ, Rhyu MG, Cottrell J, Abraham JM, Biden K, Simms L, Leggett B, Bova GS, Frank T, Powell SM, Sugimura H, Young J, Harpaz N, Shimizu K, Matsubara N, Meltzer SJ: Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res 1997, 57:2350-2353.
29. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000.
30. Barrett T, Edgar R: Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 2006, 411:352-369. [http://www.ncbi.nlm.nih.gov/geo/ ]
31. Ur-Rehman S, Gao Q, Mitsopoulos C, Zvelebil M: ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res Treat 2013, 139:907-921.
32. Pubmed. [www.pubmed.com ]
33. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C: Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
34. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C, Consortium T: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214.
35. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68:5405-5413.
36. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010, 9:3.
37. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF: Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008, 1:52.
38. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, Kim H, Lee HJ, Choi HY, Jung Y, Park M, Lim YS, Kim K, Shim Y, Kim BC, Lee K, Huh N, Ko C, Park K, Lee JW, Choi YS, Kim J: Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008, 14:7397-7404.
39. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010, 138:958-968.
40. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
41. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354:2419-2430.
42. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
43. Adjuvant!Online. [http://www.adjuvantonline.com/index.jsp ]
44. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, Min R, Alves P, Abyzov A, Addleman N, Bhardwaj N, Boyle AP, Cayting P, Charos A, Chen DZ, Cheng Y, Clarke D, Eastman C, Euskirchen G, Frietze S, Fu Y, Gertz J, Grubert F, Harmanci A, Jain P, Kasowski M, et al: Architecture of the human regulatory network derived from ENCODE data. Nature 2012, 489:91-100.
45. Cheng C, Min R, Gerstein M: TIP: a probabilistic method for identifying transcription factor target genes from ChIP-seq binding profiles. Bioinformatics 2011, 27:3221-3227.
46. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
47. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard P: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
48. Sorlie T, Borgan E, Myhre S, Vollan HK, Russnes H, Zhao X, Nilsen G, Lingjaerde OC, Borresen-Dale AL, Rodland E: The importance of gene-centring microarray data. Lancet Oncol 2010, 11:719-720. author reply 720-721.
49. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
50. DAVID (the Database for Annotation, Visualization and Integrated Discovery). [http://david.abcc.ncifcrf.gov/gene2gene.jsp ]
51. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
52. Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365:488-492.
53. Jenssen TK, Hovig E: Gene-expression profiling in breast cancer. Lancet 2005, 365:634-635.
54. Carroll JS, Prall OW, Musgrove EA, Sutherland RL: A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 2000, 275:38221-38229.
55. Dhillon NK, Mudryj M: Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002, 21:4626-4634.
56. Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182:311-322.
57. Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A: Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J 2013, 19:22-30.
58. Nagasako Y, Misawa K, Kohashi S, Hasegawa K, Okawa Y, Sano H, Takada A, Sato H: Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric Cancer 2003, 6:168-172.
59. Hitchcock CL: Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin Pathol 1991, 96:444-446.